- Related Products
MedEx answers any queries you might have regarding Ibrance-125 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
The main active substance of Ibrance is Palbociclib, which showed high effectiveness in the treatment of locally advanced and metastatic breast cancer. It is intended for the treatment of menopausal women, who haven’t undergone a hormonal therapy yet.
Breast cancer is one of the most common and severe oncological diseases. The drug takes a leading position in the treatment and diagnosis of this illness. Leading specialists recommend Ibrance (Palbociclib) as a first-line drug for the treatment of metastatic and inoperable form of breast cancer. The drug is available only on prescription.
Mechanism of action.
Ibrance is an inhibitor of cycline-dependent kinases stimulating the growth and replication of cancer cells. Palbociclib proves most effective in combination with letrozol, which is also prescribed for the treatment of disseminated breast cancer.
Way of use.
Palbociclib must be taken in courses. Initial dosage is 125 mg a day for 3 weeks. Then you should take a break for 1 week and repeat the course. The number of such courses is determined by the doctor, who can also correct the drug dosage depending on the clinical response to the treatment and the individual characteristics of every patient.
Principle of action.
Ibrance is an inhibitor (antagonist) of some cycline-dependent kinases. By blocking them, Ibrance greatly impedes the tumor growth.
The use of Ibrance increases the period without cancer progression from 10 to 20 months!
The use of Ibrance significantly reduces the amount of white blood cells (neutrophils), which significantly lowers the resistance to different infections. It also reduces the level of leukocytes and erythrocytes in blood. Patients may experience weakness and fatigue. The treatment may cause anemia, sickness, hair loss, lack of appetite, stomatitis, nasal bleedings and upper respiratory tract inflammation.
Effectiveness of use.
Based on the results of clinical trials, FDA approved the use of Ibrance in an accelerated procedure. This is because the study has showed a two-fold increase of survival rate without cancer progression in the patients receiving it compared to the control group. Besides, Ibrance was given the status of priority treatment, indicating that it has a high potential of increasing the safety and efficiency of therapy of complex and life-threatening pathologies. At the moment, the studies on the effectiveness of this drug are still under way.